Spellman David A
SEC CIK 1733204 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| AKBA | Akebia Therapeutics, Inc. | SVP, CFO, Treas | 446.5K | — | $98.1K | 7 | 2022-02-28 | 2023-05-16 |
Most active insiders at AKBA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Butler John P. | CEO, Pres, Dir | $86.6K | $474.4K |
| 2 | Grund Nicholas | Chief Commercial Off | — | $117.9K |
| 3 | Ostrowski Erik | SVP, CFO, CBO, Treas | — | $110.8K |
| 4 | Rucci Carolyn M. | SVP, CLO | — | $97.0K |
| 5 | Burke Steven Keith | SVP, Chief Medical Off | — | $94.0K |
| 6 | Malabre Richard C | SVP, CAO | — | $68.8K |
| 7 | FRIESON RON | Dir | — | — |
| 8 | Wolf Myles | Dir | — | — |
| 9 | Smith Cynthia | Dir | — | — |
| 10 | ADAMS ADRIAN | Dir | — | — |
Spellman David A made no open-market trades at AKBA in the last 12 months.
Transactions 7
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-18 | 2023-05-16 | AKBA | Akebia Therapeutics, Inc. | Spellman David A | SVP, CFO, Treas | S - Sale | $1.07 | -63.6K | 446.5K | -12% | -$68.0K | |
| M | 2023-03-03 | 2023-03-01 | AKBA | Akebia Therapeutics, Inc. | Spellman David A | SVP, CFO, Treas | S - Sale | $0.88 | -7,210 | 510.1K | -1% | -$6,345 |
| 2023-03-01 | 2023-02-27 | AKBA | Akebia Therapeutics, Inc. | Spellman David A | SVP, CFO, Treas | S - Sale | $0.81 | -7,539 | 517.3K | -1% | -$6,107 | |
| D | 2023-02-02 | 2023-01-31 | AKBA | Akebia Therapeutics, Inc. | Spellman David A | SVP, CFO, Treas | A - Grant | $0.00 | +196.2K | 524.8K | +60% | $0 |
| D | 2022-06-10 | 2022-06-08 | AKBA | Akebia Therapeutics, Inc. | Spellman David A | SVP, CFO, Treas | A - Grant | $0.00 | +200.0K | 328.6K | +156% | $0 |
| DM | 2022-03-02 | 2022-02-28+ | AKBA | Akebia Therapeutics, Inc. | Spellman David A | SVP, CFO, Treas | S - Sale | $2.15 | -8,203 | 128.6K | -6% | -$17.7K |
| D | 2022-03-02 | 2022-02-28 | AKBA | Akebia Therapeutics, Inc. | Spellman David A | SVP, CFO, Treas | A - Grant | $0.00 | +60.0K | 129.4K | +86% | $0 |
Purchase Sale Sale after option exercise All abbreviations